Update on antifungal resistance in Aspergillus and Candida

Clinical Microbiology and Infection

Volumn 20, Issue 6, 2014, Pages 42-48

  Arendrup, M C ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Acquired resistance; Aspergillus; Azoles; Candida; Echinocandins; Intrinsic resistance; Susceptibility testing

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; PYRROLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; BLOODSTREAM INFECTION; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDIASIS; FUNGUS ISOLATION; HUMAN; NONHUMAN; NORTHERN HEMISPHERE; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SPECIES IDENTIFICATION; DRUG EFFECTS; MICROBIOLOGY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS;

EID: 84922282356     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12513     Document Type: Review

References (70)

1. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect 2012; 18: E246-E247.
2. Rodriquez Tudela JL, Donnelly JP et al. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008; 14: 982-984.
3. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012; 18: E248-E250.
4. Hope WW, Cuenca-Estrella M, Lass-Flörl C, Arendrup MC. EUCAST technical note on Voriconazole and Aspergillus spp. Clin Microbiol Infect 2013; 19: E278-E280.
5. Arendrup MC, Chryssanthou E, Gaustad P, Koskela M, Sandven P, Fernandez V. Diagnostics of fungal infections in the Nordic countries: we still need to improve!. Scand J Infect Dis 2007; 39: 337-343.
6. Arendrup MC, Rodriguez-Tudela JL, Lass-Flörl C et al. EUCAST technical note on anidulafungin. Clin Microbiol Infect 2011; 17: E18-E20.
7. Arendrup MC, Pfaller MA. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother 2012; 56: 3965-3968.
8. Astvad KM, Perlin DS, Johansen HK, Jensen RH, Arendrup MC. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, Including the five most common Candida species. Antimicrob Agents Chemother 2013; 57: 177-182.
9. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin-B, itraconazole, and posaconazole. Clin Microbiol Infect 2012; 17: E248-E250.
10. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. The European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Candida and Micafungin, Anidulafungin and Fluconazole. Mycoses 2014; doi: 10.1111/myc.12170.
11. Lass-Flörl C, Arendrup MC, Rodriguez-Tudela JL et al. EUCAST technical note on Amphotericin B. Clin Microbiol Infect 2011; 17: E27-E29.
12. Varga J, Houbraken J, van der Lee HAL, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell 2008; 7: 630-638.
13. van der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol 2011; 49 (Suppl 1): S82-S89.
14. Alcazar-Fuoli L, Mellado E, astruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother 2008; 52: 1244-1251.
15. Perlin DS, Mellado E. Antifungal mechanisms of action and resistance. In: Latge JP, Steinbach WJ, eds. Aspergillus fumigatus and aspergillosis. Washington: ASM Press, 2009; 457-466.
16. van der Linden J, Arendrup MC, Verweij PE. SCARE. Interscience Conference on Antimicrobial Agents and Chemotherapy 2011; Abstr. M-490.
17. Denning DW, Park S, Lass-Flörl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-1129.
18. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
19. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of Azole-Resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother 2010; 54: 4545-4549.
20. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-795.
21. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-1904.
22. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob Agents Chemother 2012; 56: 6060-6061.
23. Stensvold CR, Jørgensen LN, Arendrup MC. Azole-resistant invasive aspergillosis: relationship to agriculture. Curr Fungal Infect Rep 2012; 6: 178-191.
24. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55: 4465-4468.
25. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012; 67: 362-366.
26. Kuipers S, Bruggemann RJ, de Sevaux RG et al. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother 2011; 55: 3564-3566.
27. Alanio A, Sitterle E, Liance M et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66: 371-374.
28. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-147.
29. Mortensen KL, Jensen RH, Johansen HK et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49: 2243-2251.
30. Morio F, Aubin GG, Danner-Boucher I et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 2012; 67: 1870-1873.
31. Arendrup MC, Mavridou E, Mortensen KL et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE 2010; 5: e10080.
32. Howard SJ, Cerar D, Anderson MJ et al. Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076.
33. Howard SJ, Webster I, Moore CB et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006; 28: 450-453.
34. Howard SJ, Pasqualotto AC, Denning DW. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2010; 16: 683-688.
35. Bueid A, Howard SJ, Moore CB et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-2118.
36. Camps SMT, van der Linden JWM, Li Y et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56: 10-16.
37. Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 2005; 55: 31-37.
38. Slaven JW, Anderson MJ, Sanglard D et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol 2002; 36: 199-206.
39. Camps SMT, Dutilh BE, ArendrupMCet al. Discovery of a hapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS ONE 2012; 7: e50034.
40. Arendrup MC, Jensen RH, Grif K et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis 2012; 206: 981-985.
41. Liu W, Sun Y, Chen W et al. The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother 2012; 56: 2598-2603.
42. Arendrup MC, Perkhofer S, Howard SJ et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-3511.
43. Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009; 53: 1185-1193.
44. Madureira A, Bergeron A, Lacroix C et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30: 551-554.
45. Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol 2008; 46: 1200-1206.
46. Zhao Y, Stensvold CR, Perlin DS, Arendrup MC. Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluids of patients with chronic diseases. J Antimicrob Chemother 2013; 68: 1497-1504.
47. Arendrup MC, Bruun B, Christensen JJ et al. National surveillance of fungemia in Denmark 2004-2009. J Clin Microbiol 2011; 49: 325-334.
48. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in iceland, 2000 to 2011. J Clin Microbiol 2013; 51: 841-848.
49. Poikonen E, Lyytikainen O, Anttila VJ et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10: 312.
50. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977-1981.
51. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: 532-538.
52. Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49: 3300-3308.
53. Shah DN, Yau R, Lasco TM et al. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother 2012; 56: 3239-3243.
54. Ben-Ami R, Olshtain-Pops K, Krieger M et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother 2012; 56: 2518-2523.
55. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008; 56: 126-129.
56. Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-4752.
57. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: e343-e353.
58. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010; 48: 1366-1377.
59. Oxman DA, Chow JK, Frendl G et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010; 65: 1460-1465.
60. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-1203.
61. Cuenca-Estrella M, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E, Rodriguez-Tudela JL. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2011; 55: 1794-1797.
62. Crump KR, Edlinds TD. Agricultural Fungicides May Select for Azole Antifungal Resistance in Pathogenic Candida. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC. Oct 30-Nov 2 2004; M-1684.
63. Yang YL, Lin CC, Chang TP et al. Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole. PLoS ONE 2012; 7: e34609.
64. Castelo-Branco DS, Brilhante RS, Paiva MA et al. Azole-resistant Candida albicans from a wild Brazilian porcupine (Coendou prehensilis): a sign of an environmental imbalance? Med Mycol 2013; 51: 555-560.
65. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445-452.
66. Cleveland AA, Farley MM, Harrison LH et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012; 55: 1352-1361.
67. Pfaller M, Neofytos D, Diekema D et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-331.
68. Ben-Ami R, Rahav G, Elinav H et al. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel. Clin Microbiol Infect 2013; 19: 752-756.
69. Das I, Nightingale P, Patel M, Jumaa P. Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. Int J Infect Dis 2011; 15: e759-e763.
70. Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009. Jpn J Infect Dis 2012; 65: 510-515.